Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Abasaglar

Sanofi reception

Sanofi predicts return to growth in second half

But first quarter net income drops by a third

- PMLiVE

Sanofi launches diabetes drug Lyxumia in the UK

Says drug could make multimillion pound savings for the NHS

- PMLiVE

Boehringer: Move towards trial transparency is “irreversible”

Pharma company plans to publish all scientific data

- PMLiVE

Boehringer to restructure in Southern Europe

Closes chemical plant in France as part of plans to “adapt” business structure

- PMLiVE

Boehringer: Tough HTA threatens future of German research

Drug pricing system is stifling innovation says pharma company

- PMLiVE

Novo opens doors on new US headquarters

$225m redevelopment for New Jersey life science offices

- PMLiVE

EC gives green light to new 6-in-1 childhood vaccine from Sanofi, MSD

Hexyon/Hexacima protects against diphtheria, DTP, hepatitis B, polio, meningitis and Haemophilus influenzae type B

- PMLiVE

Sanofi invests €20m in Morocco

Will also collaborate with government on diabetes, mental health, epilepsy and pharma training

- PMLiVE

Sanofi supports Clexane with Spanish VTE apps

The free iPhone, iPad and Android apps are for healthcare professionals

- PMLiVE

Sanofi’s four-strain flu vaccine Vaxigrip under review in EU

Pharma company also launches production of ingredient for malaria drug

Unfolding the biosimilar landscape in Latin America

Cost containment and safety concerns mean an ongoing tussle between payers and regulators, with the latter gaining the upper hand

- PMLiVE

Current development and marketing of biosimilar monoclonal antibodies in Latin America

An in-depth table of biosimilar products in the region

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links